External Control Arms (ECAs) offer the potential to reduce time-to-market for new therapies by eliminating the need for separate control groups. This streamlined approach allows studies to progress faster, particularly beneficial in diseases lacking treatment options. Furthermore, ECAs ensure all participants receive active treatment by comparing therapies to historical patient data, enhancing study feasibility and […]
Category: ai in clinical trial design
FDA Launches New AI Tool ‘Elsa’
The FDA has embraced artificial intelligence by launching a new AI tool named ‘Elsa.’ Built on Amazon Web Services’ GovCloud, Elsa securely handles sensitive government data without using proprietary manufacturer information. The tool was launched ahead of schedule and under budget, showcasing strong collaboration within the FDA. Elsa is already in use and is expected […]
AI-Designed Rentosertib in IPF Phase IIa Study
Insilico’s AI-designed drug, Rentosertib, shows promise in Phase IIa study for idiopathic pulmonary fibrosis (IPF). The innovative therapeutic approach combines AI-powered target identification and molecular design, marking a significant advancement in the pharmaceutical industry. IPF poses significant clinical challenges, and Rentosertib offers potential clinical benefits for patients with this debilitating disease. While the initial results […]
